Lipoprotein Disorder

In a real-world cohort, people with the highest levels of lipoprotein(a) had the greatest risk for long-term major adverse CV events, regardless of whether they had atherosclerotic CVD at baseline, researchers reported.

A study recently showed that adults who experienced abuse or neglect from caretakers were less likely to have ideal cardiovascular health.

High lipoprotein(a), a relatively common finding in patients undergoing CABG, was associated with increased risk for all-cause death after surgery, researchers reported.

PHILADELPHIA — In a phase 1 study, lepodisiran was well-tolerated and produced dose-dependent reductions in lipoprotein(a) concentrations in adults without CVD who had elevated lipoprotein(a) levels.

Lipoprotein(a) was associated with prevalent and incident aortic valve calcification and calcium progression in participants without aortic stenosis, researchers reported.

An analysis of U.K. Biobank data found that lipoprotein(a) may impact atrial fibrillation risk. Researchers said the link was independent of lipoprotein(a)’s effect on atherosclerotic CVD. It was the top story in cardiology last week.

Lipoprotein(a) may have a causal role in incident atrial fibrillation risk, independent of its effect on atherosclerotic CVD, according to an analysis of U.K. Biobank data.

Elevated levels of lipoprotein(a) and coronary artery calcium were associated with risk for atherosclerotic CVD, researchers reported in the Journal of the American College of Cardiology.

Utilizing commercially available assays, researchers demonstrated the feasibility of evaluating the specific atherogenic contributions of lipoprotein(a) in cholesterol at the National Lipid Association Scientific Sessions.